The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study.

BACKGROUND AND AIMS There is limited evidence on the relationship between retention in opioid agonist treatment for opioid dependence and characteristics of treatment prescribers. This study estimated retention in buprenorphine and methadone treatment and its relationship with person, treatment and prescriber characteristics. DESIGN Retrospective longitudinal study. SETTING New South Wales, Australia. PARTICIPANTS People entering the opioid agonist treatment programme for the first time between August 2001 and December 2015. MEASUREMENTS Time in opioid agonist treatment (primary outcome) was modelled using a generalized estimating equation model to estimate associations with person, treatment and prescriber characteristics. FINDINGS The impact of medication type on opioid agonist treatment retention reduced over time; the risk of leaving treatment when on buprenorphine compared with methadone was higher among those who entered treatment earlier [e.g. 2001-03: odds ratio (OR) = 1.59, 95% confidence interval (CI) = 1.45-1.75] and lowest among those who entered most recently (2013-15: OR = 1.23, 95% CI = 1.11-1.36). In adjusted analyses, risk of leaving was reduced among people whose prescriber had longer tenure of prescribing (e.g. 3 versus 8 years: OR = 0.94, 95% CI = 0.93-0.95) compared with prescribers with shorter tenure. Aboriginal and Torres Strait Islander people, being of younger age, past-year psychosis disorder and having been convicted of more criminal charges in the year prior to treatment entry were associated with increased risk of leaving treatment. CONCLUSION In New South Wales, Australia, retention in buprenorphine treatment for opioid dependence, compared with methadone, has improved over time since its introduction in 2001. Opioid agonist treatment retention is affected not only by characteristics of the person and his or her treatment, but also of the prescriber, with those of longer prescribing tenure associated with increased retention of people in opioid agonist treatment.

[1]  S. Nielsen,et al.  Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes. , 2020, Drug and alcohol dependence.

[2]  G. Dore,et al.  Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study , 2020, BMJ Open.

[3]  F. Boland,et al.  Retention of patients in opioid substitution treatment: A systematic review , 2020, PloS one.

[4]  A. Ritter,et al.  Alcohol and other drug (AOD) staffing and their workplace: examining the relationship between clinician and organisational workforce characteristics and treatment outcomes in the AOD field , 2020, Drugs: Education, Prevention and Policy.

[5]  R. Irizarry.  ggplot2 , 2019, Introduction to Data Science.

[6]  Z. Xi,et al.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine , 2019, Neuropharmacology.

[7]  D. Henderson,et al.  Long-Term Retention in an Outpatient Behavioral Health Clinic With Buprenorphine. , 2019, The American journal on addictions.

[8]  O. Amram,et al.  Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets. , 2018, Drug and alcohol dependence.

[9]  H. Shulha,et al.  High‐intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis , 2018, Addiction.

[10]  T. Dobbins,et al.  Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study , 2018, BMJ Open.

[11]  L. McCandless,et al.  Associations between methadone maintenance treatment and crime: a 17‐year longitudinal cohort study of Canadian provincial offenders , 2018, Addiction.

[12]  N. Shcherbakova,et al.  Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder , 2018, The Annals of pharmacotherapy.

[13]  D. Raistrick,et al.  Prescribers’ views and experiences of assessing the appropriateness of prescribed medications in a specialist addiction service , 2017, International Journal of Clinical Pharmacy.

[14]  H. Hagan,et al.  Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta‐analysis , 2017, Addiction.

[15]  L. Degenhardt,et al.  Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies , 2017, British Medical Journal.

[16]  T. Fahey,et al.  J-shaped relationship between supervised methadone consumption and retention in methadone maintenance treatment (MMT) in primary care: National cohort study. , 2017, Drug and alcohol dependence.

[17]  E. Quinn,et al.  Long-term retention in Office Based Opioid Treatment with buprenorphine. , 2017, Journal of substance abuse treatment.

[18]  J. Eibl,et al.  The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario , 2017, Harm Reduction Journal.

[19]  Lampros Samartzis,et al.  Opioid substitution therapy: Lowering the treatment thresholds. , 2016, Drug and alcohol dependence.

[20]  C. Timko,et al.  Retention in medication-assisted treatment for opiate dependence: A systematic review , 2016, Journal of addictive diseases.

[21]  M. Herdener,et al.  A comprehensive model of treatment participation in chronic disease allowed prediction of opioid substitution treatment participation in Zurich, 1992-2012. , 2015, Journal of clinical epidemiology.

[22]  Lei Zhang,et al.  Investigation of Repeat Client Drop-Out and Re-Enrolment Cycles in Fourteen Methadone Maintenance Treatment Clinics in Guangdong, China , 2015, PloS one.

[23]  David Moher,et al.  The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines , 2015, PloS one.

[24]  K. O’grady,et al.  Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention. , 2015, Journal of substance abuse treatment.

[25]  Chia-Chun Hung,et al.  Factors Associated with Methadone Treatment Duration: A Cox Regression Analysis , 2015, PloS one.

[26]  T. Dobbins,et al.  A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. , 2015, Addiction.

[27]  Dominic Julien,et al.  Psychological Predictors of Retention in a Low-Threshold Methadone Maintenance Treatment for Opioid Addicts: A 1-Year Follow-Up Study , 2015, Substance use & misuse.

[28]  T. Clausen,et al.  Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study. , 2014, Addictive behaviors.

[29]  M. Kreek,et al.  Methadone Maintenance Treatment Experience in Macao – Prospective Follow-up for Initial 4.5 Years , 2013, Journal of psychoactive drugs.

[30]  Alison Ritter,et al.  Subsidising patient dispensing fees: the cost of injecting equity into the opioid pharmacotherapy maintenance system. , 2012, Drug and alcohol review.

[31]  J. Long,et al.  A National Study of the Retention of Irish Opiate Users in Methadone Substitution Treatment , 2012, The American journal of drug and alcohol abuse.

[32]  P. Vickerman,et al.  Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[33]  M. Asbridge,et al.  Physicians’ attitudes towards office-based delivery of methadone maintenance therapy: results from a cross-sectional survey of Nova Scotia primary-care physicians , 2012, Harm Reduction Journal.

[34]  J. Stirling,et al.  Dual Diagnosis Competency among Addiction Treatment Staff: Training Levels, Training Needs and the Link to Retention , 2010, European Addiction Research.

[35]  W. Hall,et al.  Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. , 2009, Drug and alcohol dependence.

[36]  Y. MacNab,et al.  Proportional hazards frailty models for recurrent methadone maintenance treatment. , 2009, American journal of epidemiology.

[37]  T. Kosten,et al.  Opioid dependence treatment: options in pharmacotherapy , 2009, Expert opinion on pharmacotherapy.

[38]  H. Moriarty,et al.  Drug injecting in patients in New Zealand Methadone Maintenance Treatment programs: an anonymous survey. , 2009, Drug and alcohol review.

[39]  T. Koepsell,et al.  Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users. , 2009, Addiction.

[40]  C. Cunningham,et al.  Factors affecting willingness to provide buprenorphine treatment. , 2009, Journal of substance abuse treatment.

[41]  M. Kreek,et al.  One-Year and Cumulative Retention as Predictors of Success in Methadone Maintenance Treatment: A Comparison of Two Clinics in the United States and Israel , 2008, Journal of addictive diseases.

[42]  G. Bigelow,et al.  QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. , 2007, Archives of internal medicine.

[43]  Patrick J Heagerty,et al.  Marginal modeling of nonnested multilevel data using standard software. , 2006, American journal of epidemiology.

[44]  K. Humphreys,et al.  Predictors of retention in methadone programs: a signal detection analysis. , 2006, Drug and alcohol dependence.

[45]  A. Bond,et al.  Interactions on Mixing Diazepam With Methadone or Buprenorphine in Maintenance Patients , 2006, Journal of clinical psychopharmacology.

[46]  J. Bell,et al.  Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. , 2006, Drug and alcohol dependence.

[47]  W. van den Brink,et al.  Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. , 2005, Drug and alcohol dependence.

[48]  P. Friedmann,et al.  Does retention matter? Treatment duration and improvement in drug use. , 2003, Addiction.

[49]  K. Preston,et al.  Acute administration of buprenorphine in humans: partial agonist and blockade effects. , 1995, The Journal of pharmacology and experimental therapeutics.

[50]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[51]  R. Allard,et al.  Predictors of methadone program non-retention for opioid analgesic dependent patients. , 2013, Journal of substance abuse treatment.

[52]  R P Mattick,et al.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2008, The Cochrane database of systematic reviews.